CN103690922A - Traditional Chinese medicinal composition for treating polycystic ovarian syndrome and application thereof - Google Patents
Traditional Chinese medicinal composition for treating polycystic ovarian syndrome and application thereof Download PDFInfo
- Publication number
- CN103690922A CN103690922A CN201310739992.5A CN201310739992A CN103690922A CN 103690922 A CN103690922 A CN 103690922A CN 201310739992 A CN201310739992 A CN 201310739992A CN 103690922 A CN103690922 A CN 103690922A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- medicine composition
- polycystic ovarian
- ovarian syndrome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 28
- 201000010065 polycystic ovary syndrome Diseases 0.000 title claims abstract description 25
- 206010036049 Polycystic ovaries Diseases 0.000 title claims abstract description 22
- 239000003814 drug Substances 0.000 claims description 34
- 210000000582 semen Anatomy 0.000 claims description 13
- XOJVHLIYNSOZOO-SWOBOCGESA-N Arctiin Chemical compound C1=C(OC)C(OC)=CC=C1C[C@@H]1[C@@H](CC=2C=C(OC)C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=CC=2)C(=O)OC1 XOJVHLIYNSOZOO-SWOBOCGESA-N 0.000 claims description 9
- 241001250596 Pleione Species 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 6
- 239000002994 raw material Substances 0.000 claims description 6
- 239000003826 tablet Substances 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 230000016087 ovulation Effects 0.000 abstract description 5
- 230000005906 menstruation Effects 0.000 abstract description 4
- 241000208368 Euonymus alatus Species 0.000 abstract description 3
- 230000013632 homeostatic process Effects 0.000 abstract description 3
- 230000035935 pregnancy Effects 0.000 abstract description 3
- 240000005528 Arctium lappa Species 0.000 abstract description 2
- 235000003130 Arctium lappa Nutrition 0.000 abstract description 2
- 244000077995 Coix lacryma jobi Species 0.000 abstract description 2
- 241000096284 Gynochthodes officinalis Species 0.000 abstract description 2
- 244000273928 Zingiber officinale Species 0.000 abstract description 2
- 235000006886 Zingiber officinale Nutrition 0.000 abstract description 2
- 241000159213 Zygophyllaceae Species 0.000 abstract description 2
- 235000008397 ginger Nutrition 0.000 abstract description 2
- MUKYLHIZBOASDM-UHFFFAOYSA-N 2-[carbamimidoyl(methyl)amino]acetic acid 2,3,4,5,6-pentahydroxyhexanoic acid Chemical compound NC(=N)N(C)CC(O)=O.OCC(O)C(O)C(O)C(O)C(O)=O MUKYLHIZBOASDM-UHFFFAOYSA-N 0.000 abstract 1
- 235000008078 Arctium minus Nutrition 0.000 abstract 1
- 241000758794 Asarum Species 0.000 abstract 1
- 241000766380 Iphigenia Species 0.000 abstract 1
- 239000008361 herbal raw material Substances 0.000 abstract 1
- 235000009165 saligot Nutrition 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- 239000012567 medical material Substances 0.000 description 9
- 229940079593 drug Drugs 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 230000003203 everyday effect Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 2
- 244000192528 Chrysanthemum parthenium Species 0.000 description 2
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 235000008384 feverfew Nutrition 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 230000027758 ovulation cycle Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 201000005670 Anovulation Diseases 0.000 description 1
- 206010002659 Anovulatory cycle Diseases 0.000 description 1
- 241000758795 Aristolochiaceae Species 0.000 description 1
- 241001435059 Artemisia argyi Species 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 241000345998 Calamus manan Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 241000208365 Celastraceae Species 0.000 description 1
- 235000007354 Coix lacryma jobi Nutrition 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 102000009151 Luteinizing Hormone Human genes 0.000 description 1
- 108010073521 Luteinizing Hormone Proteins 0.000 description 1
- 241000607292 Maguireothamnus speciosus Species 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 241001348732 Paraprenanthes yunnanensis Species 0.000 description 1
- 241001457446 Pleione yunnanensis Species 0.000 description 1
- 241000800405 Spatholobus suberectus Species 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 241001533104 Tribulus terrestris Species 0.000 description 1
- 206010047998 Withdrawal bleed Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 231100000552 anovulation Toxicity 0.000 description 1
- 235000020980 bad eating habits Nutrition 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- GKIRPKYJQBWNGO-OCEACIFDSA-N clomifene Chemical compound C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(\Cl)C1=CC=CC=C1 GKIRPKYJQBWNGO-OCEACIFDSA-N 0.000 description 1
- 229960003608 clomifene Drugs 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000745 gonadal hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 201000010066 hyperandrogenism Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 235000012950 rattan cane Nutrition 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
- 229960002256 spironolactone Drugs 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 239000001841 zingiber officinale Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a traditional Chinese medicinal composition for treating polycystic ovarian syndrome. The traditional Chinese medicinal composition comprises the following Chinese herbal raw materials in part by weight: 26-36 parts of caulis spatholobi, 8-14 parts of dry ginger, 26-36 parts of winged euonymus twig, 18-25 parts of Indian iphigenia bulb, 18-25 parts of morinda officinalis, 8-14 parts of folium artemisiae argyi, 8-14 parts of caltrop, 8-14 parts of burdock, 18-25 parts of asarum and 26-36 parts of coix seed. The traditional Chinese medicinal composition for treating the polycystic ovarian syndrome can improve the pregnancy rate, promote normal ovulation and menstruation and maintain homeostasis so as to improve the cure rate.
Description
Technical field
The present invention relates to a kind of Chinese medicine composition and application for the treatment of polycystic ovarian syndrome, belong to technical field of Chinese medicines.
Background technology
Polycystic ovarian syndrome (Polycystic Ovary Syndrome) is the modal endocrine regulation disease of gynecological, its etiology unknown, with Chronic anovulation (or rare ovum of sending a manuscript to the compositor), insulin resistant (Insulin Resistance, IR) and excessive androgen mass formed by blood stasis (Hyperandrogenism) clinical syndrome that is feature, be period of duration female acyesis, menoxenia most commonly encountered diseases because of one of.Its pathogenesis is complicated, thinks at present heredity (gene mutation) and the coefficient result of environment.At society, due to factors such as people's operating pressure is large, rhythm of life fast, Bad Eating Habit, make increasing women suffer from this disease.Polycystic ovarian syndrome Epidemiological study in the past shows that its sickness rate is 5%～10%; Western medical treatment be take hormone therapy as main, and curative effect is unstable, and side effect is large.
Summary of the invention
The object of the present invention is to provide a kind of Chinese medicine composition of more safe and reliable treatment polycystic ovarian syndrome.
The object of the present invention is achieved like this:
Treat a Chinese medicine composition for polycystic ovarian syndrome, by the traditional Chinese medicinal material raw materials of following weight portion, be prepared from: Caulis Spatholobi 26-36 part, Rhizoma Zingiberis 8-14 part, Ramulus Euonymi 26-36 part, Pseudobulbus Cremastrae Seu Pleiones 18-25 part, Radix Morindae Officinalis 18-25 part, Folium Artemisiae Argyi 8-14 part, Fructus Tribuli 8-14 part, Fructus Arctii 8-14 part, Herba Asari 18-25 part, Semen Coicis 26-36 part.
Preferably you, the Chinese medicine composition of described treatment polycystic ovarian syndrome as above, it is prepared from by the traditional Chinese medicinal material raw materials of following weight portion: Caulis Spatholobi 30-32 part, Rhizoma Zingiberis 10-12 part, Ramulus Euonymi 30-32 part, Pseudobulbus Cremastrae Seu Pleiones 20-23 part, Radix Morindae Officinalis 20-23 part, Folium Artemisiae Argyi 10-12 part, Fructus Tribuli 10-12 part, Fructus Arctii 10-12 part, Herba Asari 20-23 part, Semen Coicis 30-32 part.
In most preferred embodiment of the present invention, Chinese medicine composition as above is prepared from by the traditional Chinese medicinal material raw materials of following weight portion: 30 parts of Caulis Spatholobis, 12 parts of Rhizoma Zingiberiss, 30 parts of Ramulus Euonymis, 22 parts of Pseudobulbus Cremastrae Seu Pleioness, 22 parts of Radix Morindae Officinaliss, 12 parts of Folium Artemisiae Argyis, 12 parts of Fructus Tribulis, 12 parts of Fructus Arctiis, 22 parts of Herba Asaris, 30 parts of Semen Coiciss.
Further preferably, the Chinese medicine composition for the treatment of polycystic ovarian syndrome as above is oral formulations.
Again further preferably, the Chinese medicine composition for the treatment of polycystic ovarian syndrome as above is oral liquid, granule, tablet or capsule.
By clinical application research, find, the medicine composite for curing polycystic ovarian syndrome being prepared from by above-mentioned Chinese crude drug can improve pregnancy rate, and short ovary ovulation and menorrhea are risen, and safeguard homeostasis, improve cure rate.Therefore, second object of the present invention is to provide a kind of new medical use, i.e. the application of above-mentioned Chinese medicine composition in the Chinese medicine of preparation treatment polycystic ovarian syndrome.
Chinese crude drug of the present invention has following source: Caulis Spatholobi is selected from the dry rattan of pulse family Leguminosae plant spatholobus suberectus Spatholobus suberectusDunn; Rhizoma Zingiberis is selected the dry rhizome of zingiber Zingiber officinale Rosc.; Ramulus Euonymi is again winged euonymus, Celastraceae burning buss winged euonymus Euonymus alatus (Thunb.) Sieb., with root, with wing branch and leaf be used as medicine; Pseudobulbus Cremastrae Seu Pleiones is selected the dry pseudobulb of orchid Pleione yunnanensis P. yunnansis Rolfe; Radix Morindae Officinalis is selected the dry root of Maguireothamnus speciosus Radix Morindae Officinalis Morinda officinalis How; Folium Artemisiae Argyi is selected the dried leaves of feverfew Chinese mugwort Artemisia argyi Levl. et Vant.; Fructus Tribuli is selected the dry mature fruit of zygophyllaceae plant Fructus Tribuli Tribulus terrestris L.; Fructus Arctii is selected from the dry mature fruit of feverfew Fructus Arctii Arctium lappa L.; Herba Asari is selected the whole herb with root of aristolochiaceae plant Herba Asari, Herba Asari and Seoul Herba Asari; Semen Coicis is selected the kernel of grass Semen Coicis Coix lacryma-jobi L. var. meyuan (Romen.) Stapf.
The method that above-mentioned each Chinese crude drug is prepared into oral liquid comprises the steps: to take and cleans up and dry Caulis Spatholobi, Rhizoma Zingiberis, Ramulus Euonymi, Pseudobulbus Cremastrae Seu Pleiones, Radix Morindae Officinalis, Folium Artemisiae Argyi, Fructus Tribuli, Fructus Arctii, Herba Asari and Semen Coicis, merge, decoct with water twice, collecting decoction, while being evaporated to 70 ℃, relative density is 1.15-1.20, adding ethanol makes to reach 75-85% containing the percent by volume of alcohol amount, stir, standing, filter, when filtrate decompression is concentrated into 70 ℃, relative density is 1.10-1.20 and reclaims ethanol and obtain concentrated solution, concentrated solution is added to water and adjuvant is mixed with oral liquid.
Compared with prior art, tool of the present invention has the following advantages and is progressive significantly: (1) good effect; Adopt traditional Chinese medicine composition for treating polycystic ovarian syndrome of the present invention can improve pregnancy rate, short ovary ovulation and menorrhea are risen, and safeguard homeostasis, improve cure rate; (2) safe; Because medicine of the present invention is by adopting Chinese medicine material to be prepared from, toxicity is low, and patient's medication is safer.
The specific embodiment
Below by embodiment, further illustrate the present invention.Embodiments of the invention are only used for illustrating the present invention, rather than limitation of the present invention, under design prerequisite of the present invention, the simple modifications of preparation method of the present invention are all belonged to the scope of protection of present invention.
Embodiment 1
Crude drug prescription: 3 kilograms of Caulis Spatholobis, 1.2 kilograms of Rhizoma Zingiberiss, 3 kilograms of Ramulus Euonymis, 2.2 kilograms of Pseudobulbus Cremastrae Seu Pleioness, 2.2 kilograms of Radix Morindae Officinaliss, 1.2 kilograms of Folium Artemisiae Argyis, 1.2 kilograms of Fructus Tribulis, 1.2 kilograms of Fructus Arctiis, 2.2 kilograms of Herba Asaris, 3 kilograms of Semen Coiciss.
Preparation method: the medical material that takes above-mentioned recipe quantity merges, decoct with water twice, adding for the first time water is 10 times of amounts of medical material weight, decoct 2h, adding for the second time water is 8 times of amounts of medical material weight, decoct 1.5h, collecting decoction, while being evaporated to 70 ℃ at 0.08MPa, 70 ℃, relative density is 1.15, adds 95% (v/v) ethanol and makes to reach 75% (v/v) containing alcohol amount, stirs, standing over night, filter, when filtrate concentrating under reduced pressure under 0.08MPa, 65 ℃ of conditions becomes to 65 ℃, relative density is 1.15g/mL, adds water and sucrose is mixed with oral liquid.
Embodiment 2
Crude drug prescription: 3.5 kilograms of Caulis Spatholobis, 1 kilogram of Rhizoma Zingiberis, 3.2 kilograms of Ramulus Euonymis, 1.8 kilograms of Pseudobulbus Cremastrae Seu Pleioness, 2.2 kilograms of Radix Morindae Officinaliss, 1.4 kilograms of Folium Artemisiae Argyis, 0.9 kilogram of Fructus Tribuli, 1.4 kilograms of Fructus Arctiis, 1.8 kilograms of Herba Asaris, 3.6 kilograms of Semen Coiciss.
Preparation method: the medical material that takes above-mentioned recipe quantity merges, decoct with water twice, adding for the first time water is 10 times of amounts of medical material weight, decoct 2h, adding for the second time water is 8 times of amounts of medical material weight, decoct 1.5h, collecting decoction, while being evaporated to 70 ℃ at 0.08MPa, 70 ℃, relative density is 1.15, adds 95% (v/v) ethanol and makes to reach 85% (v/v) containing alcohol amount, stirs, standing over night, filter, when filtrate concentrating under reduced pressure under 0.08MPa, 65 ℃ of conditions becomes to 65 ℃, relative density is 1.15g/mL, adds water and sucrose is mixed with oral liquid.
Embodiment 3
Crude drug prescription: 2.6 kilograms of Caulis Spatholobis, 0.8 kilogram of Rhizoma Zingiberis, 2.6 kilograms of Ramulus Euonymis, 2.5 kilograms of Pseudobulbus Cremastrae Seu Pleioness, 2.5 kilograms of Radix Morindae Officinaliss, 0.8 kilogram of Folium Artemisiae Argyi, 1.4 kilograms of Fructus Tribulis, 0.8 kilogram of Fructus Arctii, 2.2 kilograms of Herba Asaris, 3 kilograms of Semen Coiciss.
Preparation method: the medical material that takes above-mentioned recipe quantity merges, decoct with water twice, adding for the first time water is 10 times of amounts of medical material weight, decoct 2h, adding for the second time water is 8 times of amounts of medical material weight, decoct 1.5h, collecting decoction, while being evaporated to 70 ℃ at 0.08MPa, 70 ℃, relative density is 1.20, adds 95% (v/v) ethanol and makes to reach 80% (v/v) containing alcohol amount, stirs, standing over night, filter, when filtrate concentrating under reduced pressure under 0.08MPa, 65 ℃ of conditions becomes to 65 ℃, relative density is 1.15g/mL, adds water and sucrose is mixed with oral liquid.
The effectiveness study of embodiment 4 Chinese medicine composition of the present invention to patients with polycystic ovary syndrome
57 routine patients with polycystic ovary syndrome, year mean age (26.2 ± 3.8); Marriageable age 2-9, all patients all make a definite diagnosis and meet polycystic ovarian syndrome standard through B ultrasonic, 6 detections of gonadal hormone.It is divided into test group and matched group at random.Test group 29 examples wherein, matched group 28 examples.Two groups of patients, at aspect difference not statistically signigicants such as age, marriageable age, the state of an illness, have the comparability of curative effect aspect.
Matched group patient gives spironolactone sheet 40mg, and every day 2 times is oral, serve on 20d; Diformin tablet 0.5g, every day 3 times is oral, serve on to occurring normal ovulation drug withdrawal.Menstrual cycle or withdrawal bleeding 5d start oral clomiphene 50mg, and be total to 5d 1 every day, adds VITAMIN C TABLET 200mg 3 times every day simultaneously.Test group patient adds and uses Chinese medicinal formulae of the present invention on the treatment basis of matched group: Caulis Spatholobi 30g, Rhizoma Zingiberis 12g, Ramulus Euonymi 30g, Pseudobulbus Cremastrae Seu Pleiones 22g, Radix Morindae Officinalis 22g, Folium Artemisiae Argyi 12g, Fructus Tribuli 12g, Fructus Arctii 12g, Herba Asari 22g, Semen Coicis 30g.Be decocted in water for oral dose, in menstruation, within the 5th day, start to take, 1 dose of every day is oral at twice.Two groups of patients all be take 20d as 1 course for the treatment of, 3 courses for the treatment of of continuous use.After treatment finishes, the curative effect of adding up two groups of patients by following evaluation criterion:
Cure: clinical symptoms is obviously improved, occur ovulation, continuous 3 cycles of menstruation rule are above or become pregnant, and LH/FSH (serum follicule-stimulating hormone (FSH)/lutropin), T (serum testosterone) value declines and recovers normal;
Effective: clinical symptoms is improved, and menstruation rule occurs again irregular less than 2 all after dates, LH/FSH, T value decline but do not return to normal level;
Invalid: clinical symptoms is not improved, menstrual cycle is still irregular, and LH/FSH, T value decline not obvious.
Two groups of patients are after treatment, and test group total effective rate 96.6%, apparently higher than matched group 67.9%.Concrete result of the test is in Table 1.
The comparison of table 1 liang group patient clinical curative effect
Claims (6)
1. a Chinese medicine composition for the treatment of polycystic ovarian syndrome, is characterized in that: described Chinese medicine composition is prepared from by the traditional Chinese medicinal material raw materials of following weight portion: Caulis Spatholobi 26-36 part, Rhizoma Zingiberis 8-14 part, Ramulus Euonymi 26-36 part, Pseudobulbus Cremastrae Seu Pleiones 18-25 part, Radix Morindae Officinalis 18-25 part, Folium Artemisiae Argyi 8-14 part, Fructus Tribuli 8-14 part, Fructus Arctii 8-14 part, Herba Asari 18-25 part, Semen Coicis 26-36 part.
2. treat according to claim 1 the Chinese medicine composition of polycystic ovarian syndrome, it is characterized in that: described Chinese medicine composition is prepared from by the traditional Chinese medicinal material raw materials of following weight portion: Caulis Spatholobi 30-32 part, Rhizoma Zingiberis 10-12 part, Ramulus Euonymi 30-32 part, Pseudobulbus Cremastrae Seu Pleiones 20-23 part, Radix Morindae Officinalis 20-23 part, Folium Artemisiae Argyi 10-12 part, Fructus Tribuli 10-12 part, Fructus Arctii 10-12 part, Herba Asari 20-23 part, Semen Coicis 30-32 part.
3. treat according to claim 2 the Chinese medicine composition of polycystic ovarian syndrome, it is characterized in that: described Chinese medicine composition is prepared from by the traditional Chinese medicinal material raw materials of following weight portion: 30 parts of Caulis Spatholobis, 12 parts of Rhizoma Zingiberiss, 30 parts of Ramulus Euonymis, 22 parts of Pseudobulbus Cremastrae Seu Pleioness, 22 parts of Radix Morindae Officinaliss, 12 parts of Folium Artemisiae Argyis, 12 parts of Fructus Tribulis, 12 parts of Fructus Arctiis, 22 parts of Herba Asaris, 30 parts of Semen Coiciss.
4. according to the Chinese medicine composition for the treatment of polycystic ovarian syndrome described in claim 1-3 any one, it is characterized in that: described Chinese medicine composition is oral formulations.
5. the Chinese medicine composition for the treatment of polycystic ovarian syndrome according to claim 4, is characterized in that: described oral formulations is oral liquid, granule, tablet or capsule.
6. the application of Chinese medicine composition in the medicine of preparation treatment polycystic ovarian syndrome described in claim 1-3 any one.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310739992.5A CN103690922B (en) | 2013-12-30 | 2013-12-30 | A kind of Chinese medicine composition and application for the treatment of polycystic ovarian syndrome |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310739992.5A CN103690922B (en) | 2013-12-30 | 2013-12-30 | A kind of Chinese medicine composition and application for the treatment of polycystic ovarian syndrome |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103690922A true CN103690922A (en) | 2014-04-02 |
| CN103690922B CN103690922B (en) | 2015-08-19 |
Family
ID=50352692
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310739992.5A Active CN103690922B (en) | 2013-12-30 | 2013-12-30 | A kind of Chinese medicine composition and application for the treatment of polycystic ovarian syndrome |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103690922B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105168418A (en) * | 2015-10-14 | 2015-12-23 | 刘瑞莲 | Composition for treating polycystic ovarian syndrome and preparation method |
| CN105663836A (en) * | 2016-02-26 | 2016-06-15 | 李晓峰 | Pharmaceutical composition for preventing polycystic ovarian syndrome polycystic ovarian syndrome recurrent spontaneous abortion |
| CN116211900A (en) * | 2023-03-28 | 2023-06-06 | 微康益生菌(苏州)股份有限公司 | Microecological viable bacteria preparation for improving polycystic ovary syndrome, and preparation method and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101496862A (en) * | 2009-03-19 | 2009-08-05 | 王新民 | Chinese medicinal composition for treating infertility and preparation method thereof |
| CN101912511A (en) * | 2010-08-09 | 2010-12-15 | 杨素梅 | Chinese medicinal preparation for treating qi-blood deficiency polycystic ovary syndrome |
| CN102319405A (en) * | 2011-09-30 | 2012-01-18 | 张鸿翔 | Traditional Chinese medicine composition for treating polycystic ovary syndrome |
-
2013
- 2013-12-30 CN CN201310739992.5A patent/CN103690922B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101496862A (en) * | 2009-03-19 | 2009-08-05 | 王新民 | Chinese medicinal composition for treating infertility and preparation method thereof |
| CN101912511A (en) * | 2010-08-09 | 2010-12-15 | 杨素梅 | Chinese medicinal preparation for treating qi-blood deficiency polycystic ovary syndrome |
| CN102319405A (en) * | 2011-09-30 | 2012-01-18 | 张鸿翔 | Traditional Chinese medicine composition for treating polycystic ovary syndrome |
Non-Patent Citations (2)
| Title |
|---|
| 郭梅珍: "浅谈多囊卵巢综合症之中医研究", 《中国中医基础医学杂志》 * |
| 钟娜莲等: "中医药治疗多囊卵巢综合症致不孕症６０例", 《中国中医药现代远程教育》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105168418A (en) * | 2015-10-14 | 2015-12-23 | 刘瑞莲 | Composition for treating polycystic ovarian syndrome and preparation method |
| CN105663836A (en) * | 2016-02-26 | 2016-06-15 | 李晓峰 | Pharmaceutical composition for preventing polycystic ovarian syndrome polycystic ovarian syndrome recurrent spontaneous abortion |
| CN116211900A (en) * | 2023-03-28 | 2023-06-06 | 微康益生菌(苏州)股份有限公司 | Microecological viable bacteria preparation for improving polycystic ovary syndrome, and preparation method and application thereof |
| CN116211900B (en) * | 2023-03-28 | 2023-12-22 | 微康益生菌(苏州)股份有限公司 | Microecological viable bacteria preparation for improving polycystic ovary syndrome, and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103690922B (en) | 2015-08-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112891399A (en) | Traditional Chinese medicine composition and application and preparation method thereof | |
| CN104922543A (en) | Medicine composite for treating amenorrhea and preparation method thereof | |
| CN101011544A (en) | Gout rapid recovery pill(capsule) and preparation technique thereof | |
| CN103690922B (en) | A kind of Chinese medicine composition and application for the treatment of polycystic ovarian syndrome | |
| CN103611082A (en) | Weight-reducing traditional Chinese medicine composition | |
| CN103432545A (en) | Medicament for allaying fever of child and preparation method thereof | |
| CN103330865A (en) | Medicine for curing non-alcoholic steatohepatitis and preparation method thereof | |
| CN101912567B (en) | Chinese medicinal prescription for treating chronic myocarditis | |
| CN101045152A (en) | Traditional Chinese medicine composition for treating chronic pelvic inflammatory disease concomitant inflammatory swelling | |
| CN100478017C (en) | Cathartic medicine composition | |
| CN100509025C (en) | A medicine for treating diabetes | |
| CN102552520B (en) | Blood circulation-promoting and pain-stopping medicament and preparation process and application thereof | |
| CN101904935A (en) | Chinese medicinal composition for improving immunity of organisms, tonifying middle-jiao and qi and treating canine distemper | |
| CN101579405A (en) | Traditional Chinese medicine for curing constipation and preparation method thereof | |
| CN101264314A (en) | Medicaments assembly for clearing heat and detoxication, activating blood circulation and removing stasis, and diminishing inflammation and reducing pain | |
| CN104056177A (en) | Traditional Chinese medicine composition for treating otitis media | |
| CN103830620A (en) | Traditional Chinese medicine for treating phytophotodermatitis | |
| CN1292275A (en) | Chinese medicine preparation for curing postpartum disease of woman | |
| CN102743658B (en) | Traditional Chinese medicinal composition for treating urticaria | |
| CN100411672C (en) | A medicinal composition for treatment of psoriasis | |
| CN104162043A (en) | Traditional Chinese medicine used for treatment of allergic nodular cutaneous vasculitis | |
| CN103893621A (en) | Traditional Chinese medicament for treating senile vaginitis | |
| CN103566219A (en) | Traditional Chinese medicine composition for treating cold | |
| CN1274360C (en) | Antiphlogistic and antitussive medicine powder | |
| CN103520475B (en) | A kind of pharmaceutical composition being used for the treatment of skin pruritus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C53 | Correction of patent of invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Zhou Yanbin Inventor before: Liu Xuejian |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: LIU XUEJIAN TO: ZHOU YANBIN |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20170503 Address after: 226200 Hopewell Town, Qidong, Jiangsu, Nantong Patentee after: Qidong Jiulong shunzhou toy factory Address before: 266200 Jimo, Qingdao, the Yellow River, No. two, No. Road, building 25, building 182 Patentee before: Wang Xueyan |
|
| TR01 | Transfer of patent right |